California 2021-2022 Regular Session

California Assembly Bill AB265

Introduced
1/15/21  
Introduced
1/15/21  
Refer
1/28/21  
Report Pass
3/24/21  
Report Pass
3/24/21  
Refer
3/24/21  
Refer
3/24/21  
Refer
4/14/21  
Refer
4/14/21  

Caption

Medi-Cal: reimbursement rates.

Impact

The proposed changes are expected to have a positive impact on healthcare providers by potentially allowing for higher reimbursement rates than previously capped. This could be particularly beneficial in ensuring that clinical laboratory services remain financially viable and accessible to low-income populations benefiting from Medi-Cal. The bill seeks to adjust the reimbursement structure to better reflect actual market conditions and costs faced by laboratory service providers.

Summary

Assembly Bill 265, introduced by Assembly Member Petrie-Norris, proposes significant changes to the reimbursement rates for clinical laboratory services under the Medi-Cal program in California. This bill aims to amend Section 14105.22 of the Welfare and Institutions Code by removing the existing requirement that reimbursement rates not exceed 80 percent of the lowest maximum allowance established by the federal Medicare Program for similar services. Instead, it intends to establish a methodology that allows for a more flexible approach to pricing that aligns with what other payers and Medicaid programs pay for these services.

Contention

However, the bill is not without controversy. Removing the 80 percent cap may lead to concerns about the potential for increased costs to the Medi-Cal program and state budgets. Some stakeholders may argue that this amendment could ultimately lead to higher out-of-pocket costs for patients or increased demand for services that may strain the Medi-Cal budget. As the bill moves through legislative discussions, it is anticipated that stakeholders will raise questions regarding the long-term sustainability of the proposed reimbursement changes and their implications for both providers and recipients of Medi-Cal services.

Companion Bills

No companion bills found.

Similar Bills

CA AB1327

Medi-Cal: reimbursement rates.

CA AB601

Medi-Cal: reimbursement.

CA AB659

Medi-Cal: reimbursement rates.

CA SB339

Medi-Cal: laboratory rates.

CA SB912

Biomarker testing.

CA SB1234

Family Planning, Access, Care, and Treatment Program.

CA SB1191

Medi-Cal: pharmacogenomic testing.

CA SB306

Sexually transmitted disease: testing.